Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Magrolimab plus aza: phase 1b data in MDS/AML

David Sallman • 8 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab

Magrolimab is a first-in-class antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on malignant cells. Blocking CD47 with magrolimab may enable the body’s immune system to find and eliminate these cells. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the ongoing phase 1 trial (NCT03248479) of magrolimab in combination with azacitidine in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals